AOD-9604 vs Tesamorelin: A Practical Breakdown for Patients

AOD-9604 at a glance:

• Drug class: Metabolic / longevity research peptide
• Route: subcutaneous injection in research
• Typical frequency: no established human regimen
• Half-life: typically short systemically

Both options compared on this page are legitimate choices. The differences below are real but mostly modest. The bigger swing factors are usually outside the molecule itself.

Mechanism

AOD-9604: These peptides target mitochondrial function, AMPK signaling, or other metabolic pathways implicated in aging and metabolic disease. Most evidence is preclinical.

Tesamorelin: Tesamorelin is a synthetic GHRH analog stabilized for once-daily injection. Approved for reducing excess visceral fat in HIV-associated lipodystrophy.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

AOD-9604: Improvements in insulin sensitivity, exercise capacity, or markers of cellular aging in animal models.

Tesamorelin: Visceral adipose tissue reduction of 15-18% over 26 weeks in HIV-lipodystrophy trials.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• limited human data
• injection-site reactions
• arthralgia
• myalgia
• flushing
• edema

Important risks worth knowing for both:

• unknown long-term effects
• fluid retention
• carpal tunnel syndrome
• glucose intolerance

Cost

AOD-9604: pricing varies. Tesamorelin: $3,000-$4,000/month without insurance.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for AOD-9604 cost and Tesamorelin cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between AOD-9604 and Tesamorelin, either is a defensible choice in most cases.

Switching Between Them

Switching from AOD-9604 to Tesamorelin (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

If you and your clinician are split between AOD-9604 and a comparator, you're probably in a "no wrong answer" zone. Pick the one with better access for you and reassess in 3 months.

Frequently Asked Questions

Related Reading

• AOD-9604 101: A Plain-English Guide for 2026
• AOD-9604 Side Effects Decoded: What's Normal vs. What Isn't
• Real AOD-9604 Results: What 6 and 12 Months Actually Look Like
• AOD-9604 Price Decoded: Insurance, Coupons, and Cash-Pay Options
• NAD+ 101: A Plain-English Guide for 2026
• NAD+ Side Effects Decoded: What's Normal vs. What Isn't

Sources

• Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015;21:443.
• Birk AV et al. The Mitochondrial-Targeted Peptide SS-31 Selectively Improves Mitochondrial Function. JASN 2013;24:1250.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.